跳到正文

诺和诺德(阿尔及利亚)

争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 7 条

  1. 2026

    对礼来提起虚假广告诉讼

    诺和诺德在新泽西州起诉礼来,指控礼来针对糖尿病和肥胖症药物的广告具有重大误导性,因为其涉嫌歪曲比较性临床证据。该争议尚未解决,代表两家GLP-1制造商之间竞争的重大升级。

  2. 2026

    宾夕法尼亚州就涉嫌胰岛素价格串通起诉胰岛素制造商和药品福利管理机构

    提起诉讼

    宾夕法尼亚州起诉 Eli Lilly and Co.、Novo Nordisk Inc.、Sanofi-Aventis US LLC 及数家药品福利管理机构,指控它们串通抬高胰岛素价格。诉讼要求进行结构性改革、支付赔偿金及罚款。该诉讼将 Novo Nordisk Inc. 列为被指控参与价格串通的胰岛素制造商之一。

    当事方说明的目的. 追回该县称已向这些公司支付的超过 2700 万美元。

    来源摘录

    • The pharmaceutical companies included in the Pennsylvania case are Eli Lilly and Co., Novo Nordisk Inc., and Sanofi-Aventis US LLC. Several PBMs are included as defendants, including Express Scripts, Caremark, and Optum RX.
    • The state’s lawsuit seeks to institute “structural changes to ensure the companies lower costs to fair market prices and enable options for patients,” restitution for Pennsylvanians harmed by the scheme, and payments including financial penalties paid by the companies and the costs of the state’s investigation and lawsuit.
    • Last week, Pennsylvania sued a group of pharmaceutical companies and PBMs for allegedly colluding to raise insulin prices unnecessarily.
  3. 2024

    GLP-1药物围绕定价、可及性和供应的争议

    Ozempic和Wegovy的快速需求加剧了公众和政治对美国定价、保险覆盖、短缺、不平等可及性以及药品分销和药品福利体系作用的批评。诺和诺德通过扩大生产和可及性倡议作出回应,而批评者继续质疑可负担性。

  4. 2021

    诺和诺德召回部分产品样品

    宣布召回

    诺和诺德自愿召回1,468份Levemir、Tresiba、Fiasp、NovoLog和Xultophy产品样品,原因是这些样品储存温度低于要求。召回仅涉及产品样品,不涉及广泛分销至药房或邮购服务的产品;公司表示,尚未收到与此次召回相关的严重不良事件或伤害报告。

    品牌回应

    • 整改 — Novo Nordisk

      Novo Nordisk has notified all physician offices that received affected samples and requested all impacted samples be returned.

    来源摘录

    • Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level.
    • Novo Nordisk has not received any reports of serious adverse events or injuries related to this recall.
    • These products are being recalled because they were stored at temperatures below storage requirements.
  5. 2013

    丹麦转让定价税务争议

    诺和诺德因转让定价争议被要求向丹麦税务机关补缴约36亿丹麦克朗。案件涉及跨国集团内部的利润分配。

  6. 2013

    肠促胰岛素药物相关的胰腺炎和胰腺癌担忧

    科学家、监管机构和诉讼当事人就是否包括Victoza在内的肠促胰岛素类糖尿病药物与胰腺副作用相关展开辩论。当时的现有证据未能确立所称因果关系,但该问题引发了产品责任诉讼和监管关注。

  7. 2010

    涉及Victoza的ABPI行为准则违规

    英国制药工业协会(ABPI)认定诺和诺德违反其行为准则,原因是未能提供Victoza的充分副作用信息,并在产品获得上市许可前进行推广。